Most Read Articles
Dr. Joseph Delano Fule Robles, 5 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

5 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
6 days ago
High levels of marijuana exposure appear to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
4 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.

Mesalazine 1,600-mg formulation noninferior to 400 mg for induction treatment of UC

01 Aug 2017

In patients with ulcerative colitis (UC), induction treatment with 3.2 mg mesalazine using two 1,600 mg tablets once-daily is as good as using four 400 mg tablets twice-daily, according to the results of a noninferority trial.

A total of 817 patients with mild-to-moderate active UC (Mayo Clinic Score >5) were treated with 3.2 g of oral mesalazine, administered as either two 1,600 mg tablets once or four 400 mg tablets twice daily. Outcomes investigated were induction of clinical and endoscopic remission at week 8. Based on response, open-label treatment with the 1,600 mg tablet continued for 26 to 30 weeks. Predictors of treatment response were also examined.

At week 8, remission occurred in 22.4 percent of patients receiving the 1,600 mg formulation and in 24.6 percent of those receiving the 400 mg formulation (absolute difference, −2.2 percent; 95 percent CI, −8.1 to 3.8; noninferiority, p=0.005). Clinical remission was significantly associated with endoscopic and histopathologic disease activity (p=0.022 and p=0.042), leucocyte concentration (p=0.014), and age (p=0.023).

At week 38, 296 of 675 patients (43.9 percent) who continued treatment with the 1,600 mg formulation were in remission, including 142 of 202 patients (70.3 percent) who received a reduced dose of mesalazine (1.6 g/d). Overall incidence of serious adverse events was low.

Oral mesalazine is the most commonly prescribed medication for patients with mild-to-moderate UC. While multitablet regimens administered two to four times daily have been shown to be safe and effective, a high-concentration formulation was developed to improve dosing convenience and ensure consistent drug release within the colon. [Gastroenterology 2015;148:1035-1058; Cochrane Database Syst Rev 2016;4:CD000543]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 5 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

5 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
6 days ago
High levels of marijuana exposure appear to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
4 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.